USC Norris Comprehensive Cancer Center and HOAG
Welcome,         Profile    Billing    Logout  
 13 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hanna, Diana
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease

Terminated
3
236
Europe, US, RoW
Voxelotor, Placebo
Pfizer
Sickle Cell Disease
08/23
11/24
NCT05630183: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer

Hourglass Jan 2024 - Jun 2024 : Results from C-800-22 trial for 2L metastatic pancreatic cancer
Recruiting
2
78
US
Botensilimab, AGEN1181, Gemcitabine, Nab-paclitaxel
Agenus Inc.
Metastatic Pancreatic Ductal Adenocarcinoma
12/24
12/24
NCT05327010: Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

Recruiting
2
88
US
BET Bromodomain Inhibitor ZEN-3694, BETi ZEN-3694, ZEN 3694, ZEN-3694, ZEN003694, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Talazoparib, BMN 673, BMN-673, BMN673
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
08/25
08/25
NCT04387071: CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

Terminated
1/2
2
US
Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, Anti-OX40 Agonist Antibody INCAGN01949, Anti-OX40 Monoclonal Antibody INCAGN0194, INCAGN 1949, INCAGN-1949, INCAGN1949, Monoclonal Antibody INCAGN01949, NCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001, ARB-1598, CMP-001, CYT 003, CYT-003
University of Southern California, National Cancer Institute (NCI)
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
12/22
12/22
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors

Recruiting
1/2
242
US
DF9001, pembrolizumab, KEYTRUDA®
Dragonfly Therapeutics, Merck Sharp & Dohme LLC
Solid Tumor, Adult
08/25
11/27
TWINPEAK, NCT05482893: Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)

Recruiting
1/2
135
US
Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine, FOLFIRINOX
Phanes Therapeutics, Merck Sharp & Dohme LLC
Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
12/27
04/28
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors

Active, not recruiting
1/2
189
US
XTX202
Xilio Development, Inc., Xilio Development, Inc
Advanced Solid Tumor
02/26
02/26
NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors

Terminated
1
46
US, RoW
GNX102
GlycoNex, Inc.
Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm
07/23
07/23
NCT03854110: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Recruiting
1
64
US
GP-2250, gemcitabine
Geistlich Pharma AG, Translational Drug Development
Pancreatic Cancer, Adult
09/24
12/24
NCT03537690: FID-007 in Treating Participants With Advanced Solid Tumors

Recruiting
1
36
US
Laboratory Biomarker Analysis, PEOX-based Polymer Encapsulated Paclitaxel FID-007, Paclitaxel in Polyethyloxazoline Polymer; FID-007; FID007 (CN); FID 007; Nanoencapsulated Paclitaxel FID-007, Pharmacokinetic Study, PHARMACOKINETIC, PK Study
University of Southern California, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
05/25
05/26
TEAD-AST-101, NCT06251310: SW-682 in Advanced Solid Tumors

Recruiting
1
186
US
SW-682, Combination Therapy
SpringWorks Therapeutics, Inc.
Advanced Solid Tumor, Mesothelioma, Malignant
01/30
06/30
ZWI-ZW171-10, NCT06523803: A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

Recruiting
1
160
Europe, US
ZW171
Zymeworks BC Inc.
Mesothelin-expressing Advanced Cancers
11/27
12/27
NCT06336902: Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients with KRAS-Mutant Metastatic Colorectal Cancer

Recruiting
1
15
US
Balstilimab, AGEN 2034, AGEN-2034, AGEN2034, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Botensilimab, AGEN 1181, AGEN-1181, AGEN1181, Anti-CTLA-4 Monoclonal Antibody AGEN1181, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dietary Intervention, Dietary Modification, intervention, dietary, Nutrition Intervention, Nutrition Interventions, Nutritional Interventions, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Vitamin C
University of Southern California, National Cancer Institute (NCI)
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC V8
01/27
01/28
NCT01802346: Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer

Active, not recruiting
N/A
130
US
dietary intervention, Dietary Modification, intervention, dietary, nutritional support, nutritional assessment, nutritional care, support, nutritional, laboratory biomarker analysis
University of Southern California, National Cancer Institute (NCI), Mayo Clinic
Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
01/25
01/26
NCT04631445: Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

Active, not recruiting
N/A
32
US
Ketogenic Diet
Translational Drug Development, Translational Genomics Research Institute
Metastatic Pancreatic Ductal Adenocarcinoma
03/25
04/25
NCT03594448: Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients

Terminated
N/A
6
US
Specimen Collection, Serial Liquid Biopsy
University of Southern California, National Cancer Institute (NCI)
Microsatellite Instability, Colorectal Cancer Stage IV
09/23
09/23
NCT03971266: Movement and Fitness Trackers in Determining Performance Status

Recruiting
N/A
68
US
Activity Monitor, Activity Tracker; Activity Tracker Device; Physical Activity Measuring Device, Media Intervention
University of Southern California, National Cancer Institute (NCI)
Malignant Neoplasm
03/25
03/26

Download Options